<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000650568"><TermName>myeloablative chemotherapy</TermName><TermPronunciation>(MY-eh-loh-a-BLAY-tiv KEE-moh-THAYR-uh-pee)</TermPronunciation><TermDefinition><DefinitionText>High-dose chemotherapy that kills cells in the bone marrow, including cancer cells. It lowers the number of normal blood-forming cells in the bone marrow, and can cause severe side effects. Myeloablative chemotherapy is usually followed by a bone marrow or stem cell transplant to rebuild the bone marrow.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000726100" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;myeloablative chemotherapy&quot;" language="en" id="_3"/><MediaLink ref="CDR0000726101" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;quimioterapia mielodepresora&quot;" language="es" id="_4"/><SpanishTermName>quimioterapia mielodepresora</SpanishTermName><SpanishTermDefinition><DefinitionText>Quimioterapia de dosis alta que destruye las células de la médula ósea, incluso las células cancerosas. Disminuye la cantidad de células hematopoyéticas normales en la médula ósea y puede causar efectos secundarios graves.   Generalmente, después de administrar la quimioterapia mielodepresora se realiza un trasplante de médula ósea o un trasplante de células madre para reconstruir la médula ósea. </DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-01-11</DateFirstPublished></GlossaryTerm>
